Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma.

Autor: Gangadhar TC; Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Savitch SL; Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Yee SS; Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Xu W; Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Huang AC; Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Institue for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Parker Institute of Immunotherapy, University of Pennsylvania, Philadelphia, PA, USA., Harmon S; Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Lieberman DB; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Soucier D; Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Fan R; Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Black TA; Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Morrissette JJD; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Salathia N; Illumina Inc., San Diego, CA, USA., Waters J; Illumina Inc., San Diego, CA, USA., Zhang S; Illumina Inc., San Diego, CA, USA., Toung J; Grail Bio, Redwood City, CA, USA., van Hummelen P; Illumina Inc., San Diego, CA, USA., Fan JB; Illumina Inc., San Diego, CA, USA., Xu X; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Amaravadi RK; Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Schuchter LM; Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Karakousis GC; Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Hwang WT; Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Department of Biostatistics & Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Carpenter EL; Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Jazyk: angličtina
Zdroj: Pigment cell & melanoma research [Pigment Cell Melanoma Res] 2018 Jan; Vol. 31 (1), pp. 73-81. Date of Electronic Publication: 2017 Oct 23.
DOI: 10.1111/pcmr.12623
Abstrakt: To determine the feasibility of liquid biopsy for monitoring of patients with advanced melanoma, cell-free DNA was extracted from plasma for 25 Stage III/IV patients, most (84.0%) having received previous therapy. DNA concentrations ranged from 0.6 to 390.0 ng/ml (median = 7.8 ng/ml) and were positively correlated with tumor burden as measured by imaging (Spearman rho = 0.5435, p = .0363). Using ultra-deep sequencing for a 61-gene panel, one or more mutations were detected in 12 of 25 samples (48.0%), and this proportion did not vary significantly for patients on or off therapy at the time of blood draw (52.9% and 37.5% respectively; p = .673). Sixteen mutations were detected in eight different genes, with the most frequent mutations detected in BRAF, NRAS, and KIT. Allele fractions ranged from 1.1% to 63.2% (median = 29.1%). Among patients with tissue next-generation sequencing, nine of 11 plasma mutations were also detected in matched tissue, for a concordance of 81.8%.
(© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje